> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Chinese Firms Asked About Counterfeit GLP-1 Drugs
- URL: https://www.fdaweb.com/chinese-firms-asked-about-counterfeit-glp-1-drugs/
- Published: 2026-01-15T12:00:00.000Z
- Updated: 2026-09-14T15:30:48.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160501

Rep. **Raja Krishnamoorthi** (D-IL), ranking member of the House Select Committee on the Strategic Competition Between the U.S. and the Chinese Communist Party, has written to three Chinese drug companies requesting detailed information about their manufacturing, labeling, and exporting of glucagon-like peptide-1 weight loss drugs and associated active pharmaceutical ingredients (APIs). In a [statement](ttps://democrats-selectcommitteeontheccp.house.gov/media/press-releases/krishnamoorthi-sends-letters-chinese-biotech-firms-regarding-illicit-and) (contains links to the letters), Krishnamoorthi cites hundreds of reports received by FDA on adverse events linked to illicit compounded GLP-1s, warning that the true scope of harm remains understudied and may be significantly underreported. He also cites a recent FBI warning that fraudulent compounded weight-loss drugs have been associated with gastrointestinal disorders, psychiatric disorders, and death.

The letters went to the Chinese Peptide Company, Hubei JXBio Biotech, and Fujian Genohope Biotech. Krishnamoorthi asked each company to supply these materials:

- a full list detailing all semaglutide (Novo Nordisk’s Wegovy) and tirzepatide (Eli Lilly’s Zepbound) products and associated APIs manufactured, sold, and shipped to U.S. customers;
- a comprehensive list of all U.S. retailers supplied by the companies or their customers;
- a description of the business relationships with U.S. compounding pharmacies or other U.S. customers;
- a description of the companies’ practices used for labeling semaglutide and tirzepatide products and associated APIs that are exported to the U.S.;
- agreements with U.S. drug compounders on labeling of semaglutide and tirzepatide products shipped into the U.S.;
- manufacturer safety assurance procedures the companies use for all manufactured semaglutide and tirzepatide products and associated APIs;
- safety and quality testing procedures used for all relevant products;
- the companies’ drug manufacturing licenses in the People’s Republic of China;
- the companies’ FDA registration, if applicable; and
- any subsidies, funding, or other benefits the companies receive from any government entity in China.